Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells $90,011.94 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Stoke Therapeutics Stock Up 0.8 %

Shares of Stoke Therapeutics stock opened at $8.33 on Friday. The firm has a market cap of $441.22 million, a PE ratio of -3.97 and a beta of 0.99. Stoke Therapeutics, Inc. has a twelve month low of $5.80 and a twelve month high of $17.58. The business has a 50-day moving average price of $9.49 and a 200 day moving average price of $11.49.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. On average, sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new stake in shares of Stoke Therapeutics in the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth approximately $124,000. Tower Research Capital LLC TRC raised its stake in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after purchasing an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in Stoke Therapeutics in the 4th quarter valued at $133,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on STOK shares. Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.